Update on new antifungal therapy

Paul Juang1

  • 1Department of Pharmacy Practice, St Louis College of Pharmacy, 4588 Parkview Place, St Louis, MO 63110, USA. pjuang@stlcop.edu

AACN Advanced Critical Care
|November 21, 2007
PubMed

Insights

New antifungal agents, micafungin, anidulafungin, and posaconazole, offer improved treatment options for invasive fungal infections. This review details their efficacy, usage, and safety profiles for clinicians.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Mycology

Background:

  • Rising rates of fungal infections, morbidity, and mortality necessitate novel antifungal therapies.
  • Echinocandins and triazoles represent key classes of antifungal medications.

Purpose of the Study:

  • To review the clinical efficacy of three new antifungal agents: micafungin, anidulafungin, and posaconazole.
  • To outline approved uses, dosages, and administration guidelines for these agents.

Main Methods:

  • Review of clinical efficacy data for micafungin, anidulafungin, and posaconazole.
  • Analysis of approved indications, dosing regimens, and administration techniques.
  • Evaluation of drug interactions, precautions, and adverse effects.

Main Results:

  • Micafungin and anidulafungin are echinocandins inhibiting 1,3-beta-D-glucan synthase.
  • Posaconazole is a triazole inhibiting ergosterol synthesis, effective against Candida and molds.
  • These agents demonstrate promising efficacy in treating and preventing invasive fungal infections.

Conclusions:

  • Micafungin, anidulafungin, and posaconazole represent significant advancements in antifungal treatment.
  • Understanding their specific mechanisms, efficacy, and safety is crucial for optimal patient care.

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...